MAUNA KEA Aktie

 

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the update of its financial calendar for the 2026 fiscal year. Events Date Q1 2026 Sales April 15, 2026 2025 Annual Results April 22, 2026 2026 Annual General Meeting June 4, 2026 Q2 2026 Sales July 21, 2026 2026 Half-Year Results October 8, 2026 Q3 2026 Sales October 20, 2026 Note: These dates are indicative and subject to adjustment. About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical intervention...

Completed Resort-wide enhancements include renovated guestrooms and suites, two new pools, a redesigned golf course and enhanced dining outlets KOHALA COAST, Hawaii, Feb. 10, 2026 /PRNewswire-PRWeb/ -- Hawaii Island's first resort, the iconic Mauna Kea Beach Hotel, originally envisioned......

Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMFPARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) January 31, 2026 192,202,823 193,286,360 193,286,360 (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recomm...

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its financial calendar for the 2026 fiscal year as well as the resumption of its participation in investor conferences. Events Date 2025 Annual Results April 9, 2026 Q1 2026 Sales April 16, 2026 2026 Annual General Meeting June 4, 2026 Q2 2026 Sales July 21, 2026 2026 Half-Year Results October 8, 2026 Q3 2026 Sales October 20, 2026 Note: These dates are indicative and subject to adjustment. After a 2025 fiscal year marked by the successful restructuring of its balance sheet and the implementation of structuring strategic partnerships, Mauna Kea Technologies wishes to share its progress and growth prospects more regularly with the financial community. In this context, Management will participate in the following events in the first half of 2026: Allinvest Securities Biomed For...

Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects – CER) Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%, +31% at CER), driven by pancreatic cyst indication CellTolerance confirmed as a second pillar of growth, with €1 million in global sales achieved in fiscal year 2025 Webinar for shareholders and investors – Thursday, January 15, 2026 at 6:00 p.m. CET Click here to register (French only)PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the fourth quarter of 2025. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “Our Q4 performance confirms a positive trend for Mauna Kea Technologies. U.S. sales accelerated for the fourth consecutive quarter, confirming the United States as our largest a...

70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second half of 2027PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the full success of its financial restructuring and of its capital increase (the "Operation"), launched yesterday following the approval of its safeguard plan (the "Plan") by the Paris Court of Economic Activities (Tribunal des Activités Économiques de Paris). This operation concludes a major restructuring that sets a solid foundation for the Company to execute its operational plan: Improved balance sheet: Equity increased by €7.7M and total gross debt reduced by €28M (from €40M to €12M). The Company is now effectively ...

Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) October 31, 2025 94,871,537 95,970,496 95,970,496 Including 1,750,000 new shares issued during the month as part of the equity financing facility (see press releases published on July 25, 2024 and April 24, 2025). (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General Meeting...

U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial team to support organic demandPARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the third quarter of 2025, up 16% at constant exchange rates (CER). Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, stated: “I am pleased with our significantly improved performance in the third quarter, reflecting the acceleration of our commercial momentum in the U.S., where we are benefiting from very positive clinical data presented earlier this year, strong support from a large group of leading physicians and attractive reimbursement. Responding to strengthening market demand, we have elected to expand our U.S. ...

Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA) Firm commitment from an investor for €2.7m, supplemented by indications of interest already exceeding the minimum targeted amount Lock-up commitment from the EIB (2 years) and a standstill agreement from the Company (6 months) to ensure capital stability Alignment of all shareholder interests through the free allocation of warrants (BSA) to existing shareholdersPARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today specifies the terms of its proposed capital increase (the "Capital Increase") as part of its safeguard plan, which was approved by a majority of the classes of affected parties as announced on October 6. The Capital Increase, for a total amount between €5 mil...

32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1 Finalization of Safeguard Plan, including Restructuring of Existing Bank Debt, Planned Equity Capital Raise, and Expected Allocation of Free Warrants to all Shareholders Webinar for shareholders and investors - Monday, October 6, 2025, at 6:00 PM CEST Registration LinkPARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its unaudited financial results for the first half of 2025 and provides a business update. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "At no time since our 2011 IPO has Mauna Kea been at such a strategic crossroads. The Safeguard Procedure we entered voluntary earlier this year has been exceedingly demanding to navi...

On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard procedure Total revenue down 5% amid weaker EMEA and ROW sales results Further steps taken to improve Mauna Kea Technologies' financial strengthPARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the first half and the first two quarters of 2025, ended June 30, 2025. First Half of 2025 Performance Summary Total revenue for the first half of 2025 amounted to €3.7m, representing a slight decline of 5% compared to H1 2024. U.S. revenue for the first half of 2025 grew by +14% as reported and +17% in constant currency, with a significant dollar depreciation against the euro, especially in Q2 2025. U.S. operations remained robust, with accelerated growth in Q2 2025: sales rose +23%...

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the availability of preparatory documents for the Combined General Meeting of June 5, 2025, to be held at 11:00 a.m. at the Company's head office at 9 rue d'Enghien, 75010 - Paris. Notice of the meeting, including the agenda, proposed resolutions and instructions for participating and voting at the meeting were published in the Bulletin des Annonces Légales Obligatoires (BALO) on April 30, 2025, bulletin n°52, announcement 2501382. This notice of meeting, together with the documents and information relating to the Combined General Meeting and the single voting form, can be accessed via the Company's website in the "Investors" > “Governance” section of the Shareholders' Meeting area, at the following address https://www.maunakeatech.com/governance/. Any sha...

Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) March 31, 2025 68,319,997 69,397,471 69,397,471 Including 200,000 new shares issued during the month as part of the equity financing facility (see press release published on July 25, 2024). (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General ...